December 13, 2023 8:05am

While eyeing with a magnifying glass on clinical results, approvals, partner/licensing’s longevity and believe it or not – patent protection

Pre-open Indications: 2 Positive, 4 Negative and 1 Sell into Strength Indications

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed!

I support Israel, mind body and spirit

Remember that overnight action in a.m. Futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Sentiment seems fleeting. My usual question, are we facing a prisoner’s dilemma -  a situation wherein algorithms acting with electronic trading interest do not achieve a continued optimal outcome for this investor group

 

The pre-open Dow futures are UP +0.15% or (+57 points), the S&P is UP +0.19% or (+8 points) as the Nasdaq is UP +0.25% or (+42 points)

U.S. stock futures inched higher Wednesday as investors await the Fed’s latest policy decision,

European markets were moving higher,

Asia-Pacific markets were mixed

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday, indexes popped, hitting their highest intraday levels since January 2022; the Dow closed UP +173.01 points or +0.48%, the S&P closed UP +21.26 points or +0.46% while the Nasdaq closed UP +100.91 points or +0.70%

Economic Data Docket:The producer price index was unchanged in November after decreasing 0.4% in October, the U.S. Bureau of Labor Statistics said. Economists polled by Dow Jones forecast a rise of 0.1%.

  • The two-day Fed meeting ends today, with a policy announcement due at 2 p.m. ET. Fed chief Jerome Powell will hold his news conference at 2:30 p.m. ET.

 

Tuesday, RegMed Investors (RMi) Closing Bell: “cell and gene therapy sector called out running the bases. Called out on first base, Monday and second, Tuesday; who’s on for the third, Wednesday?” …  https://www.regmedinvestors.com/articles/13243

  

Q4:  December – 4 positive and 4 negative closes

  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: looking for lost SHEAP …

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indication:

Tuesday’s closing price, some Monday, Friday, Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$4.01 after Monday’s +$7.01, Friday’s +$0.20, Thursday’s +$1.36 and last Wednesday’s -$0.89 following the previous Tuesday’s +$0.59 with a positive +$0.30 or +0.35% pre-open indication.

 

Negative Indications:

Tuesday’s closing price, some Monday, Friday, Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$2.96 after Monday’s +$0.88 with a negative -$1.88 or -1.08% pre-open indication.

Prime Medicine (PRME) closed down -$0.58 after Monday’s -$0.35, Friday’s -$0.06, Thursday’s +$0.17 and last Wednesday’s +$0.54 following the previous Tuesday’s -$0.22 with a negative -$0.15 or -1.98% pre-open indication.

BioLife Solutions (BLFS) closed down -$0.17 after Monday’s -$0.39 with another negative -$0.17 or -1.34% pre-open indication.

Ultragenyx Pharmaceuticals (RARE) closed up +$2.81 after Monday’s +$0.16 with a negative -$0.87 or -2% pre-open indication.

 

Positive Indications:

Tuesday’s closing price, some Monday, Friday, Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed down -$2.16 after Monday’s -$4.26, Friday’s -$5.67, Thursday’s -$0.93 and last Wednesday’s +$0.54 following the previous Tuesday’s -$0.91 with a positive +$0.13 or +022% pre-open indication.

Intellia Therapeutics (NTLA) closed down -$0.20 after Monday’s -$0.67, Friday’s -$0.76, Thursday’s -$0.08 and last Wednesday’s -$0.04 with a positive +$0.25 or +0.89% pre-open indication

 

The BOTTOM LINE:  Not changing my “tune” … I remain a skeptic, thus maintaining; investors should consider getting defensive…

  • If dead wood or too struggling share pricings are in the portfolio; especially those desperately needing a financing, lacking a partner, restructuring and just wallowing in the market …
  • I am STILL waiting for catalysts to justify recent upside appreciation as some news sinks the share pricing other than algorithmic electronic trading!
  • While optimism for December remains high, some analysts worry the run-up has been too big, too fast. <The Street>
  • Again, it might be prudent to harvest and cash in some chips following the past month’s dramatic rally.
  • It’s up to you to decide!

It's time to think ahead to December. It's usually an important month for the Nasdaq.

  • Don’t FORGET portfolio tax selling and a bit of rebalancing
  • And then comes January and with worries that the U.S. economy will be slowing down, the potential for continued Middle East violence and, of course, the real prospect of bitterly contested elections across all of the United States. <The Street>

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.